EBV-specific T-lymphocytes (allogeneic), such as EBV-CTLs
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for EBV-specific T-lymphocytes (allogeneic), such as EBV-CTLs, covering 2022-10-21 to 2022-10-21. Get the full timeline:
Most recent: Clinical Trial Update: Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies [Phase 2]